Home LiteratureArticle Details
PMID: 2751746 Published · ppublish English Journal Article

Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration.

Atherosclerosis ·Vol. 77 ·No. 2-3 ·1989-06-00 ·Pages 139-49

Malmendier CL, Lontie JF, Delcroix C, Dubois DY, Magot T, De Roy L

Abstract

Four hypertriglyceridemic patients, who had received an equilibrated high calorie diet and no lipid lowering drug for 1 month, were injected intravenously with 125I-apo C-II and 131I-apo C-III labeled homologous lipoproteins. Plasma and urine radioactivity, lipid and apolipoprotein levels were followed at regular intervals for 15 days. At the end of this first kinetic study the patients were advised to adhere for 1 month to a more restricted diet, limited in fat, and were given additionally 300 mg fenofibrate daily. After this treatment, a new kinetic study involving intravenous injection (similar to the first one) was performed. The protocols of both studies were identical. Treatment (diet plus drug) (1) reduced total cholesterol by 26 +/- 8%, triglycerides by 56 +/- 15%, apo C-II by 36 +/- 14%, and apo C-III by 48 +/- 10%; (2) modified the distribution of radioactivity between lipoproteins proportionally to the change in their mass ratio (decrease in VLDL and increase in HDL); (3) changed the kinetics of both apoproteins by rising the fractional removal rate, shortening residence time and decreasing the synthesis rate of both apolipoproteins C-II and C-III. The treatment was, however, unable to reduce the synthesis rate of apo C-III to normal, suggesting a major role of the apoprotein overproduction in the triggering of hypertriglyceridemia.

MeSH Terms
Apolipoproteins C/metabolism Fenofibrate/therapeutic use Humans Hypertriglyceridemia/diet therapy,drug therapy,metabolism Kinetics Male Propionates/therapeutic use
Chemicals
Apolipoproteins C Propionates Fenofibrate
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Malmendier C L
Fondation de Recherche sur l'Athérosclérose, Brussels, Belgium.
Lontie J F
Delcroix C
Dubois D Y
Magot T
De Roy L
Article Info
Journal
Atherosclerosis
Abbr.
Atherosclerosis
ISSN
0021-9150
Published
1989-06-00
Pages
139-49
Language
English
Region
Ireland
NLM ID
0242543
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com